• darkblurbg



  • darkblurbg

    Intralymphatic immunotherapy

    with Diamyd®


Aktieägarna i Diamyd Medical AB (publ) kallas härmed till årsstämma torsdagen den 21 november 2019, kl. 17.00 på Hotell Kung Carl, Birger Jarlsgatan 21 i Stockholm. Sista datum för anmälan är den 15 november.


 Dates for financial information and other events
Data pager
Data pager
November 21, 2019
Annual General Meeting
Annual General Meeting 2018/2019
January 22, 2020
Quarterly Report I
Quarterly Report 1 2019/2020
March 25, 2020
Quarterly Report II
Quarterly Report 2 2019/2020
June 24, 2020
Quarterly Report III
Quarterly Report 3 2019/2020

We diligently focus on advancing treatments that are safe, accessible and that intercept the disease early before complications begin to manifest.

Ulf Hannelius
President and CEO, Diamyd Medical AB


Diamyd Medical is a Swedish clinical-stage diabetes company active in the field of pharmaceutical development
The share is listed on Nasdaq First North Growth Market (ticker: DMYD B)

Read More
  • Diabetes

    10-20% of the more than 400 million living with diabetes suffer from the autoimmune form of the disease, where the immune system destroys the insulin-producing cells. Preserving the insulin producing ability may decrease the risk of complications among patients with autoimmune diabetes by 60-80 percent.

  • Products

    The antigen-specific immunotherapy Diamyd® and the regenerative and immunomodulatory therapy Remygen® are two novel disease-modifying drugs in clinical development phase, aiming to preserve and regenerate the patients’ own insulin production.

  • Clinical Trials

    The efficacy of intralymphatic administration of Diamyd® on preserving the insulin producing ability in type 1 diabetes is being confirmed in the Phase IIb trial DIAGNODE-2. The safety and efficacy of Remygen® on stimulating growth of insulin producing cells in type 1 diabetes is being evaluated for the first time in the Phase I/II trial ReGenerate-1.

Order GAD for preclinical research